Holistick is developing a device to treat common heart defects, including patent foramen ovale (PFO), a septal defect that causes a blood flow between the two atria and is observed in one out of four individuals. Three clinical studies recently published in the New England Journal of Medicine show that in patients under 60, PFO closure significantly reduces the risk of recurring stroke. These studies led the FDA to approve two devices in this indication. Unlike current metallic implants, Holistick uses flexible materials, allowing for an atraumatic PFO closure that respects the integrity of the cardiac septum.
Holistick owns the exclusive, global licensing rights for this heart-defect repair technology, jointly developed by Harvard and the Massachusetts Institute of Technology (MIT). Holistick was created by Truffle Capital, with the firm’s new BioMedTech fund.
Company’s Keywords:
<17
<
<2017
Your request has been submitted successfully.
Own or work here?